Chemed Corp. (NYSE:CHE) insider Nicholas Michael Westfall sold 10,000 shares of the company’s stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $231.00, for a total transaction of $2,310,000.00. Following the transaction, the insider now owns 13,351 shares in the company, valued at approximately $3,084,081. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Shares of Chemed Corp. (CHE) traded up $0.19 during midday trading on Tuesday, reaching $231.31. The company had a trading volume of 97,100 shares, compared to its average volume of 93,742. The stock has a market capitalization of $3,690.06, a price-to-earnings ratio of 28.46, a P/E/G ratio of 4.89 and a beta of 1.14. Chemed Corp. has a 52-week low of $145.09 and a 52-week high of $235.96. The company has a current ratio of 0.50, a quick ratio of 0.48 and a debt-to-equity ratio of 0.15.
Chemed Corp. (NYSE:CHE) last issued its earnings results on Thursday, October 26th. The company reported $2.15 EPS for the quarter, beating the Zacks’ consensus estimate of $2.00 by $0.15. The firm had revenue of $417.40 million for the quarter, compared to analyst estimates of $414.34 million. Chemed Corp. had a return on equity of 27.69% and a net margin of 4.62%. Chemed Corp.’s revenue for the quarter was up 6.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.73 earnings per share. sell-side analysts anticipate that Chemed Corp. will post 4.73 earnings per share for the current year.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Acrospire Investment Management LLC purchased a new stake in Chemed Corp. in the second quarter valued at approximately $120,000. Pacad Investment Ltd. boosted its position in Chemed Corp. by 250.0% in the second quarter. Pacad Investment Ltd. now owns 700 shares of the company’s stock valued at $143,000 after buying an additional 500 shares during the last quarter. IFP Advisors Inc boosted its position in Chemed Corp. by 1,504.5% in the third quarter. IFP Advisors Inc now owns 706 shares of the company’s stock valued at $143,000 after buying an additional 662 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Chemed Corp. by 12.8% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 731 shares of the company’s stock valued at $150,000 after buying an additional 83 shares during the last quarter. Finally, MCF Advisors LLC purchased a new stake in Chemed Corp. in the third quarter valued at approximately $152,000. Hedge funds and other institutional investors own 96.58% of the company’s stock.
Several research firms have recently issued reports on CHE. Zacks Investment Research upgraded shares of Chemed Corp. from a “hold” rating to a “buy” rating and set a $216.00 price objective on the stock in a report on Monday, September 18th. National Bank Financial upgraded shares of Chemed Corp. from a “sector perform market weight” rating to an “outperform market weight” rating in a report on Sunday, August 13th. KeyCorp began coverage on shares of Chemed Corp. in a report on Monday, August 28th. They set a “sector weight” rating on the stock. Oppenheimer Holdings, Inc. upped their price objective on shares of Chemed Corp. from $200.00 to $220.00 and gave the company an “outperform” rating in a report on Thursday, July 27th. Finally, TheStreet downgraded shares of Chemed Corp. from a “b+” rating to a “c+” rating in a report on Tuesday, July 25th. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $236.00.
About Chemed Corp.
Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The Company operates through two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.
Receive News & Ratings for Chemed Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed Corp. and related companies with MarketBeat.com's FREE daily email newsletter.